Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
QuintilesIMS
Federal Trade Commission
Daiichi Sankyo
US Army

Generated: July 16, 2019

DrugPatentWatch Database Preview

Patent: 5,981,606

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,981,606
Title: Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
Abstract:This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic TGF-beta-wound healing compositions for reducing the formation of scar tissue and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of a TGF-beta (GF) to form TGF-beta-wound healing compositions (II.A-D+GF). This invention also pertains to methods for preparing and using the TGF-beta-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.
Inventor(s): Martin; Alain (Ringoes, NJ)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/019,316
Patent Claims:see list of patent claims

Details for Patent 5,981,606

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Interferon Sciences ALFERON N INJECTION interferon alfa-n3 VIAL 103158 001 1989-10-10 ➤ Try a Free Trial Warner-Lambert Company (Morris Plains, NJ) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Queensland Health
Daiichi Sankyo
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.